<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta charset="utf-8">
<title>DailyMed - LAMISIL- terbinafine hydrochloride tablet</title>
<!--[if lt IE 9]>
        <script src="/dailymed/scripts/html5shiv.min.js"></script>
    <![endif]-->

<script src="/dailymed/scripts/modernizr-2.0.6.min.js">
</script>
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/skeleton.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/jquery.jqzoom.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/style.min.css?v=2">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/header-search.min.css">
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive.min.css">
<link rel="stylesheet" type="text/css" media="print" href=
"/dailymed/css/print.min.css"><!--[if !IE]><!-->
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive-tables.min.css"><!--<![endif]-->
<link rel="icon" href="/dailymed/images/favicons/favicon.ico" type=
"image/x-icon">
<link rel="shortcut icon" href=
"/dailymed/images/favicons/favicon.ico" type="image/x-icon">
<link rel="apple-touch-icon" sizes="57x57" href=
"/dailymed/images/favicons/apple-touch-icon-57x57.png">
<link rel="apple-touch-icon" sizes="114x114" href=
"/dailymed/images/favicons/apple-touch-icon-114x114.png">
<link rel="apple-touch-icon" sizes="72x72" href=
"/dailymed/images/favicons/apple-touch-icon-72x72.png">
<link rel="apple-touch-icon" sizes="144x144" href=
"/dailymed/images/favicons/apple-touch-icon-144x144.png">
<link rel="apple-touch-icon" sizes="60x60" href=
"/dailymed/images/favicons/apple-touch-icon-60x60.png">
<link rel="apple-touch-icon" sizes="120x120" href=
"/dailymed/images/favicons/apple-touch-icon-120x120.png">
<link rel="apple-touch-icon" sizes="76x76" href=
"/dailymed/images/favicons/apple-touch-icon-76x76.png">
<link rel="apple-touch-icon" sizes="152x152" href=
"/dailymed/images/favicons/apple-touch-icon-152x152.png">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-196x196.png" sizes="196x196">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-160x160.png" sizes="160x160">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-96x96.png" sizes="96x96">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-16x16.png" sizes="16x16">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-32x32.png" sizes="32x32">
<meta name="msapplication-config" content=
"/dailymed/images/favicons/browserconfig.xml">
<meta name="msapplication-TileColor" content="#da532c">
<meta name="msapplication-TileImage" content=
"/dailymed/images/favicons/mstile-144x144.png">
<meta name="description" content="">
<meta name="keywords" content="">
<meta name="robots" content="noimageindex, noodp, noydir">
<meta name="viewport" id="viewport" content=
"width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0"><!-- Magnific Popup core CSS file -->
<link rel="stylesheet" href="/dailymed/css/magnific-popup.min.css">
<meta name="format-detection" content="telephone=no">
</head>
<body class="inner drug-info">
<div class="container_1000 bg_shadow">
<div style="width: 0; height: 0;"><a href="#" id=
"top-of-page"></a></div>
<header>
<div class="topHeader">
<ul id="skip">
<li><a href="#skip-main-content">Skip to Main Content</a></li>
</ul>
<nav class="topHeaderNav">
<div class="topNIHLogo mobileview"><a href="http://www.nih.gov"
class="top-logo" title="National Institutes of Health" target=
"_blank"><img src="/dailymed/images/nih-toplogo.png" alt=
"NIH Logo"></a> <a href="//www.nlm.nih.gov" title=
"U.S. National Library of Medicine" target="_blank">U.S. National
Library of Medicine</a></div>
<div class="container">
<div class="sixteen columns">
<div class="topNIHLogo"><a href="http://www.nih.gov" title=
"National Institutes of Health" target="_blank"><img src=
"/dailymed/images/nih-toplogo.png" alt="NIH Logo"></a> <a href=
"//www.nlm.nih.gov" title="U.S. National Library of Medicine"
target="_blank">U.S. National Library of Medicine</a></div>
<ul>
<li class="safety"><a title="Report Adverse Events" href=
"//www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report
Adverse Events</a> <span>|</span><a title=
"FDA Safety Reporting and Recalls" href=
"http://www.fda.gov/Safety/Recalls" target=
"_blank">Recalls</a></li>
</ul>
</div>
</div>
</nav>
<div class="divider"></div>
</div>
<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png"
alt="DailyMed"></div>
<div class="bottomHeader">
<div class="header-image">
<div class="mobile-menu-btn closed hasjs" tabindex="0"></div>
<div class="mobile-menu">
<div class="mobile-menu-container">
<div class="pro-menu active">
<div class="first half">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/about-dailymed.cfm">About Dailymed</a></li>
<li><a href="/dailymed/contact-us.cfm">Contact Us</a></li>
<li>Safety Reporting &amp; Recalls
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/">Report
Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey
Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
</ul>
</div>
<div class="last half">
<ul>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-all-mapping-files.cfm">Articles &amp;
Presentations</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</div>
</div>
<a href="/dailymed/index.cfm" class="logo" title=
"DailyMed">DailyMed</a>
<div class="header-search-container">
<div id="header-search">
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all" value="all"> <label for=
"labeltype-all">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human" value="human"> <label for=
"labeltype-human">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal" value="animal"> <label for=
"labeltype-animal">Animal Drugs</label></li>
<li class="more-ways" id="header-search-more-ways"><a href="#" id=
"more-ways-button" class="more-ways-label">More ways to search</a>
<ul id="more-ways-dropdown" class="dropdown" style="display:none;">
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Label Archives</a></li>
<li><a class="external-link" href="http://pillbox.nlm.nih.gov"
target="_blank">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
</div>
</div>
<div class="mobile-search-btn" tabindex="0"></div>
<div class="header-bg"></div>
<div class="divider"></div>
</div>
<div class="bottomHeaderContent">
<div class="search mobile-search">
<div class="divider_10 nomargin mobileview"></div>
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all-2" value="all"> <label for=
"labeltype-all-2">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human-2" value="human"> <label for=
"labeltype-human-2">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal-2" value="animal"> <label for=
"labeltype-animal-2">Animal Drugs</label></li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchToolsQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
<div class="divider"></div>
<nav class="bottomHeaderNav"><noscript>
<div class="tabletnav no-js">
<div class="col">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</noscript>
<ul class="webview hasjs">
<li><a href="/dailymed/index.cfm" title="Home">Home</a></li>
<li><a href="#" title="News">News</a>
<ul class="sub-menu">
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm" title=
"FDA Guidances &amp; Info">FDA Guidances &amp; Info</a></li>
<li><a href="#" title=
"Structured Product Labeling (SPL) resources for industry professionals.">
NLM SPL Resources</a>
<ul class="sub-menu">
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><a href="#" title="Application Development Support">Application
Development Support</a>
<ul class="sub-menu">
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
<ul class="tabletview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li class="viewmore"><a href="#" title="View More">View More</a>
<ul>
<li><span>News</span>
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><span>Safety Reporting and Recalls</span>
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="//www.fda.gov/Safety/Recalls" target="_blank">FDA
Saftey Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li><span>NLM SPL Resources</span>
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><span>Application Development Support</span>
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
</li>
<li class="mobileview viewmore" tabindex="0"><a title="View More"
href="#">More ways to search</a>
<ul>
<li tabindex="0"><a title="Browse Drug Classes" href=
"/dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>
<li tabindex="0"><a title="Label Archives" href=
"/dailymed/archives/index.cfm">Label Archives</a></li>
<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool"
href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
<ul class="mobileview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li tabindex="0" class="viewmore"><a href="#" title=
"View More">View More</a>
<ul>
<li tabindex="0"><a href="/dailymed/browse-drug-classes.cfm" title=
"Browse Drug Classes">Browse Drug Classes</a></li>
<li tabindex="0"><a href="/dailymed/archives/index.cfm" title=
"Label Archives">Label Archives</a></li>
<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title=
"Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</nav>
<div class="divider_10 nomargin"></div>
</div>
</div>
<div class="divider"></div>
</div>
</header>
<div id="skip-main-content"></div>
<div class="container">
<div class="main-content">
<div class="header long">
<div class="header-top">
<h1>Label: <span class="long-title">LAMISIL- terbinafine
hydrochloride tablet<br></span></h1>
</div>
<ul class="tools">
<li class="rss"><a href="#modal-label-rss" class="modal-open">Label
RSS</a></li>
<li class="share">Share <noscript>: JavaScript needed for Sharing
tools</noscript> <!-- AddThis Button BEGIN -->
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0ALAMISIL%2D%20Terbinafine%20Hydrochloride%20Tablet%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D7c6c1494%2Dfb92%2D4442%2Dbcff%2D764b77397495%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="display: block;"><span style=
"left: -9999px; position: absolute;">Bookmark &amp;
Share</span><img style="width:17px" src=
"/dailymed/images/addthis-image.jpg"></a></div>
<script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <!-- AddThis Button END --></li>
</ul>
</div>
<div class="four columns sidebar" id="leftmenu">
<section>
<article>
<div class="w-photos">
<div class="mod drug-photos">
<h2><a>View Package Photos</a></h2>
<ul>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=lamisil-tablets-02.jpg&amp;setid=7c6c1494-fb92-4442-bcff-764b77397495"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="0"><img id="zoom_1" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=lamisil-tablets-02.jpg&amp;setid=7c6c1494-fb92-4442-bcff-764b77397495"
src=
"image.cfm?type=img&amp;name=lamisil-tablets-02.jpg&amp;setid=7c6c1494-fb92-4442-bcff-764b77397495"
data-photo-type="package"> </a></li>
</ul>
</li>
</ul>
</div>
<div class="mod drug-photos">
<h2><a>VIEW DRUG PHOTOS</a></h2>
<div class="no-pill-photo-warning-drug-info">DailyMed is no longer
displaying pill images from RxImage. For more information, <a href=
"#no-pill-photo-warning-modal" class="modal-open">click
here</a>.</div>
</div>
</div>
<div class="mod-wrap">
<div class="mod blue-list page-jump">
<h2><a href="#drug-information">Drug Label Info</a></h2>
</div>
<div class="mod blue-list orange">
<h2><a href="#">Safety</a></h2>
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls/" target=
"_blank">FDA Safety Recalls</a></li>
<li><a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22TERBINAFINE%22+%29"
target="_blank">Presence in Breast Milk</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">Related Resources</a></h2>
<ul>
<li><a href=
"//vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=TERBINAFINE"
target="_blank">Medline Plus</a></li>
<li><a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=TERBINAFINE"
target="blank">Clinical Trials</a></li>
<li><a href="#" id="pubmed-menu">PubMed</a>
<ul>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=TERBINAFINE[All%20Fields]"
title="Link opens new window for All Citations" target="pubmed">All
Citations</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=TERBINAFINE/AE"
title="Link opens new window for Adverse Effects" target=
"pubmed">Adverse Effects</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=TERBINAFINE/TU"
title="Link opens new window for Therapeutic Use" target=
"pubmed">Therapeutic Use</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=TERBINAFINE/PD"
title="Link opens new window for Pharmacology" target=
"pubmed">Pharmacology</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=TERBINAFINE[All%20Fields]%20AND%20Clinical%20Trial[ptyp]"
title="Link opens new window for Clinical Trials" target=
"pubmed">Clinical Trials</a></li>
</ul>
</li>
<li><a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=APRD00508&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">More Info For This Drug</a></h2>
<ul>
<li><a href="#modal-label-archives" class="modal-open">View Label
Archives</a></li>
<li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>
<li><a href="#modal-label-rss" class="modal-open">Get Label RSS
Feed</a></li>
</ul>
</div>
</div>
</article>
</section>
</div>
<div class="content-wide">
<article>
<ul class="drug-information">
<li><strong><a class="tip" rel="tooltip" title=
"&lt;b&gt;NDC (National Drug Code)&lt;/b&gt; - Each drug product is assigned this unique number which can be found on the drug's outer packaging."
href="#">NDC Code(s):</a></strong> <span id=
"item-code-s">0078-0179-05, 0078-0179-15</span></li>
<li style="list-style: none"><span id="item-code-s"></span></li>
<li><span id="item-code-s"></span></li>
<li><span id="item-code-s"><strong>Packager:</strong> Novartis
Pharmaceuticals Corporation</span></li>
</ul>
<ul class="drug-information">
<li><span id="item-code-s"><strong>Category:</strong> <span id=
"category" class="orangetext">HUMAN PRESCRIPTION DRUG
LABEL</span></span></li>
<li><strong>DEA Schedule:</strong> <span id=
"dea-schedule">None</span></li>
<li><strong>Marketing Status:</strong> <span id=
"marketing-status">New Drug Application</span></li>
</ul>
<div id="drug-information" class="toggle">
<h2><a id="druglabel"></a>Drug Label Information</h2>
<p class="date">Updated February 2, 2015</p>
<p class="orangetext">If you are a consumer or patient please visit
<a class="audience-context-switch consumer" href=
"/dailymed/drugInfo.cfm?setid=7c6c1494-fb92-4442-bcff-764b77397495&amp;audience=consumer">
this version.</a></p>
<ul class="tools">
<li class="download">Download DRUG LABEL INFO: <a download=""
class="pdf" href=
"/dailymed/getFile.cfm?setid=7c6c1494-fb92-4442-bcff-764b77397495&amp;type=pdf&amp;name=7c6c1494-fb92-4442-bcff-764b77397495"
target="_blank">PDF</a> <a download="" class="xml" href=
"/dailymed/getFile.cfm?setid=7c6c1494-fb92-4442-bcff-764b77397495&amp;type=zip&amp;name=LAMISIL"
target="_blank">XML</a></li>
<li class="print"><a href=
"/dailymed/fda/fdaDrugXsl.cfm?setid=7c6c1494-fb92-4442-bcff-764b77397495&amp;type=display"
target="_blank">Print Drug Label Info</a></li>
</ul>
<div class="drug-label-sections">
<div class="control-nav show-js"><a class="open-all" href="#">View
All Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
<ul>
<li><a href="#">HIGHLIGHTS OF PRESCRIBING INFORMATION</a>
<div id="Highlights" class=" Highlights toggle-content closed">
<div class="HighlightsDisclaimer"><span class="Bold">These
highlights do not include all the information needed to use LAMISIL
Tablets safely and effectively.</span><br>
<span class="Bold">See full prescribing information for LAMISIL
Tablets.</span><br>
<br>
<span class="Bold">LAMISIL<span class="Sup">®</span> (terbinafine
hydrochloride) Tablets, 250 mg For oral use</span><br>
<span class="Bold">Initial U.S. Approval: 1992</span><br></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Lamisil Tablets are an allylamine antifungal
indicated for the treatment of onychomycosis of the toenail or
fingernail due to dermatophytes (tinea unguium) (<a href=
"#s1">1</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul class="Disc">
<li>Fingernail onychomycosis: One 250 mg tablet, once daily for 6
weeks (<a href="#s2">2</a>)<br></li>
<li>Toenail onychomycosis: One 250 mg tablet, once daily for 12
weeks (<a href="#s2">2</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Tablet, 250 mg (<a href="#s3">3</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta">Lamisil Tablets are contraindicated in
individuals with a history of allergic reaction to oral terbinafine
because of the risk of anaphylaxis. (<a href="#s4">4</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<ul class="Disc">
<li>Liver failure, sometimes leading to liver transplant or death,
has occurred with the use of oral terbinafine. Obtain pretreatment
serum transaminases. Discontinue Lamisil Tablets if liver injury
develops. (<a href="#s5p1">5.1</a>, <a href=
"#s5p8">5.8</a>)<br></li>
<li>Taste disturbance, including taste loss, has been reported with
the use of Lamisil Tablets. Taste disturbance can be severe, may be
prolonged, or may be permanent. Discontinue Lamisil Tablets if
taste disturbance occurs. (<a href="#s5p2">5.2</a>)<br></li>
<li>Smell disturbance, including loss of smell, has been reported
with the use of Lamisil Tablets. Smell disturbance may be
prolonged, or may be permanent. Discontinue Lamisil Tablets if
smell disturbance occurs. (<a href="#s5p3">5.3</a>)<br></li>
<li>Depressive symptoms have been reported with terbinafine use.
Prescribers should be alert to the development of depressive
symptoms. (<a href="#s5p4">5.4</a>)<br></li>
<li>Severe neutropenia has been reported. If the neutrophil count
is <span class="Underline">&lt;</span>1000 cells/mm<span class=
"Sup">3</span>, Lamisil Tablets should be discontinued. (<a href=
"#s5p5">5.5</a>)<br></li>
<li>Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema
multiforme, exfoliative dermatitis, bullous dermatitis, and drug
reaction with eosinophilia and systemic symptoms (DRESS) syndrome
have been reported with oral terbinafine use. If signs or symptoms
of drug reaction occur, treatment with Lamisil Tablets should be
discontinued. (<a href="#s5p6">5.6</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Common (&gt;2% of patients treated with
Lamisil Tablets) reported adverse events include headache,
diarrhea, rash, dyspepsia, liver enzyme abnormalities, pruritus,
taste disturbance, nausea, abdominal pain, and flatulence.
(<a href="#s6p1">6.1</a>)</p>
<p class="Highlighta"><span class="Bold"><br>
<br>
To report SUSPECTED ADVERSE REACTIONS, contact Novartis
Pharmaceuticals Corporation at 1-888-669-6682 or FDA at
1-800-FDA-1088 or www.fda.gov/medwatch.</span></p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta">Terbinafine is an inhibitor of CYP450 2D6
isozyme and has an effect on metabolism of desipramine. Drug
interactions have also been noted with cimetidine, fluconazole,
cyclosporine, rifampin, and caffeine. (<a href="#s7p1">7.1</a>)</p>
<p class="Highlighta"></p>
</div>
</div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING
INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 2/2015</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">FULL PRESCRIBING INFORMATION: CONTENTS*</a>
<div id="Index" class=" Index toggle-content closed">
<h1><a href="#section-1" class="toc">1 INDICATIONS AND
USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND
ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND
STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND
PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Hepatotoxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Taste Disturbance
Including Loss of Taste</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Smell Disturbance
Including Loss of Smell</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Depressive
Symptoms</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Hematologic
Effects</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Serious
Skin/Hypersensitivity Reactions</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Lupus
Erythematosus</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Laboratory
Monitoring</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials
Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing
Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Drug-Drug
Interactions</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Food
Interactions</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC
POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Renal
Impairment</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL
PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of
Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2
Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3
Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL
TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis,
Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology
and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND
HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING
INFORMATION</a></h1>
<dl class="Footnote">
<dt><a name="footnote-content" href="#footnote-reference-content"
id="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing
information are not listed.</dd>
</dl>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">1 INDICATIONS AND USAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34067-9"><a name="s1" id="s1"></a> <a name="section-1" id=
"section-1"></a>
<p class="First">Lamisil (terbinafine hydrochloride) Tablets are
indicated for the treatment of onychomycosis of the toenail or
fingernail due to dermatophytes (tinea unguium).</p>
<p>Prior to initiating treatment, appropriate nail specimens for
laboratory testing [potassium hydroxide (KOH) preparation, fungal
culture, or nail biopsy] should be obtained to confirm the
diagnosis of onychomycosis.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">2 DOSAGE AND ADMINISTRATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34068-7"><a name="s2" id="s2"></a> <a name="section-2" id=
"section-2"></a>
<p class="First">Fingernail onychomycosis: One 250 mg tablet once
daily for 6 weeks.</p>
<p>Toenail onychomycosis: One 250 mg tablet once daily for 12
weeks.</p>
<p>The optimal clinical effect is seen some months after
mycological cure and cessation of treatment. This is related to the
period required for outgrowth of healthy nail.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">3 DOSAGE FORMS AND STRENGTHS</a>
<div class="Section toggle-content closed" data-sectioncode=
"43678-2"><a name="s3" id="s3"></a> <a name="section-3" id=
"section-3"></a>
<p class="First">Tablet, 250 mg white to yellow-tinged white
circular, bi-convex, beveled tablets imprinted with “LAMISIL” in
circular form on one side and code “250” on the other side.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">4 CONTRAINDICATIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34070-3"><a name="s4" id="s4"></a> <a name="section-4" id=
"section-4"></a>
<p class="First">Lamisil Tablets are contraindicated in individuals
with a history of allergic reaction to oral terbinafine because of
the risk of anaphylaxis.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">5 WARNINGS AND PRECAUTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"43685-7"><a name="s5" id="s5"></a> <a name="section-5" id=
"section-5"></a>
<div class="Section" data-sectioncode="42229-5"><a name="s5p1" id=
"s5p1"></a> <a name="section-5.1" id="section-5.1"></a>
<h2>5.1 Hepatotoxicity</h2>
<p class="First">Cases of liver failure, some leading to liver
transplant or death, have occurred with the use of Lamisil Tablets
in individuals with and without preexisting liver disease.</p>
<p>In the majority of liver cases reported in association with use
of Lamisil Tablets, the patients had serious underlying systemic
conditions. The severity of hepatic events and/or their outcome may
be worse in patients with active or chronic liver disease.
Treatment with Lamisil Tablets should be discontinued if
biochemical or clinical evidence of liver injury develops.</p>
<p>Lamisil Tablets are not recommended for patients with chronic or
active liver disease. Before prescribing Lamisil Tablets, liver
function tests should be performed since hepatotoxicity may occur
in patients with and without pre-existing liver disease. Periodic
monitoring of liver function tests is recommended. Lamisil should
be immediately discontinued in case of elevation of liver function
tests. Patients prescribed Lamisil Tablets should be warned to
report immediately to their physician any symptoms of persistent
nausea, anorexia, fatigue, vomiting, right upper abdominal pain or
jaundice, dark urine, or pale stools. Patients with these symptoms
should discontinue taking oral terbinafine, and the patient’s liver
function should be immediately evaluated.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s5p2" id=
"s5p2"></a> <a name="section-5.2" id="section-5.2"></a>
<h2>5.2 Taste Disturbance Including Loss of Taste</h2>
<p class="First">Taste disturbance, including taste loss, has been
reported with the use of Lamisil Tablets. It can be severe enough
to result in decreased food intake, weight loss, anxiety, and
depressive symptoms. Taste disturbance may resolve within several
weeks after discontinuation of treatment, but may be prolonged
(greater than 1 year), or may be permanent. If symptoms of a taste
disturbance occur, Lamisil Tablets should be discontinued.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s5p3" id=
"s5p3"></a> <a name="section-5.3" id="section-5.3"></a>
<h2>5.3 Smell Disturbance Including Loss of Smell</h2>
<p class="First">Smell disturbance, including loss of smell, has
been reported with the use of Lamisil Tablets. Smell disturbance
may resolve after discontinuation of treatment, but may be
prolonged (greater than 1 year), or may be permanent. If symptoms
of a smell disturbance occur, Lamisil Tablets should be
discontinued.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s5p4" id=
"s5p4"></a> <a name="section-5.4" id="section-5.4"></a>
<h2>5.4 Depressive Symptoms</h2>
<p class="First">Depressive symptoms have occurred during
postmarketing use of Lamisil Tablets. Prescribers should be alert
to the development of depressive symptoms, and patients should be
instructed to report depressive symptoms to their physician.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s5p5" id=
"s5p5"></a> <a name="section-5.5" id="section-5.5"></a>
<h2>5.5 Hematologic Effects</h2>
<p class="First">Transient decreases in absolute lymphocyte counts
(ALCs) have been observed in controlled clinical trials. In
placebo-controlled trials, 8/465 subjects receiving Lamisil Tablets
(1.7%) and 3/137 subjects receiving placebo (2.2%) had decreases in
ALC to below 1000/mm<span class="Sup">3</span> on 2 or more
occasions. In patients with known or suspected immunodeficiency,
physicians should consider monitoring complete blood counts if
treatment continues for more than 6 weeks. Cases of severe
neutropenia have been reported. These were reversible upon
discontinuation of Lamisil Tablets, with or without supportive
therapy. If clinical signs and symptoms suggestive of secondary
infection occur, a complete blood count should be obtained. If the
neutrophil count is ≤1000 cells/mm<span class="Sup">3</span>,
Lamisil Tablets should be discontinued and supportive management
started.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s5p6" id=
"s5p6"></a> <a name="section-5.6" id="section-5.6"></a>
<h2>5.6 Serious Skin/Hypersensitivity Reactions</h2>
<p class="First">There have been postmarketing reports of serious
skin/hypersensitivity reactions [e.g., Stevens-Johnson Syndrome,
toxic epidermal necrolysis, erythema multiforme, exfoliative
dermatitis, bullous dermatitis, and drug reaction with eosinophilia
and systemic symptoms (DRESS) syndrome]. Manifestations of DRESS
syndrome may include cutaneous reaction (such as rash or
exfoliative dermatitis), eosinophilia, and one or more organ
complications such as hepatitis, pneumonitis, nephritis,
myocarditis, and pericarditis. If progressive skin rash or
signs/symptoms of the above drug reactions occur, treatment with
Lamisil Tablets should be discontinued.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s5p7" id=
"s5p7"></a> <a name="section-5.7" id="section-5.7"></a>
<h2>5.7 Lupus Erythematosus</h2>
<p class="First">During postmarketing experience, precipitation and
exacerbation of cutaneous and systemic lupus erythematosus have
been reported in patients taking Lamisil Tablets. Lamisil Tablets
should be discontinued in patients with clinical signs and symptoms
suggestive of lupus erythematosus.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s5p8" id=
"s5p8"></a> <a name="section-5.8" id="section-5.8"></a>
<h2>5.8 Laboratory Monitoring</h2>
<p class="First">Measurement of serum transaminases (ALT and AST)
is advised for all patients before taking Lamisil Tablets.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">6 ADVERSE REACTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34084-4"><a name="s6" id="s6"></a> <a name="section-6" id=
"section-6"></a>
<div class="Section" data-sectioncode="42229-5"><a name="s6p1" id=
"s6p1"></a> <a name="section-6.1" id="section-6.1"></a>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely
varying conditions, adverse reaction rates in the clinical trials
of a drug cannot be directly compared to rates in the clinical
trials of another drug and may not reflect the rates observed in
practice.</p>
<p>The most frequently reported adverse events observed in the 3
US/Canadian placebo-controlled trials are listed in the table
below. The adverse events reported encompass gastrointestinal
symptoms (including diarrhea, dyspepsia, and abdominal pain), liver
test abnormalities, rashes, urticaria, pruritus, and taste
disturbances. Changes in the ocular lens and retina have been
reported following the use of Lamisil Tablets in controlled trials.
The clinical significance of these changes is unknown. In general,
the adverse events were mild, transient, and did not lead to
discontinuation from study participation.</p>
<div class="scrollingtable">
<table>
<colgroup>
<col width="147">
<col width="147">
<col width="147">
<col width="147">
<col width="147"></colgroup>
<tfoot>
<tr>
<td align="left" colspan="5">
<dl class="Footnote">
<dt><a href="#footnote-reference-1" name="footnote-1" id=
"footnote-1">*</a></dt>
<dd>Liver enzyme abnormalities ≥2x the upper limit of normal
range.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule" align="center" colspan="2"><span class=
"Bold">Adverse Event</span></td>
<td class="Toprule" align="center" colspan="2"><span class=
"Bold">Discontinuation</span></td>
</tr>
<tr>
<td class="Toprule"></td>
<td class="Toprule" align="center"><span class="Bold">Lamisil
Tablets</span></td>
<td class="Toprule" align="center"><span class=
"Bold">Placebo</span></td>
<td class="Toprule" align="center"><span class="Bold">Lamisil
Tablets</span></td>
<td class="Toprule" align="center"><span class=
"Bold">Placebo</span></td>
</tr>
<tr>
<td></td>
<td align="center"><span class="Bold">(%)</span></td>
<td align="center"><span class="Bold">(%)</span></td>
<td align="center"><span class="Bold">(%)</span></td>
<td align="center"><span class="Bold">(%)</span></td>
</tr>
<tr>
<td></td>
<td align="center"><span class="Bold">n=465</span></td>
<td align="center"><span class="Bold">n=137</span></td>
<td align="center"><span class="Bold">n=465</span></td>
<td align="center"><span class="Bold">n=137</span></td>
</tr>
<tr>
<td class="Toprule">Headache</td>
<td class="Toprule" align="center">12.9</td>
<td class="Toprule" align="center">9.5</td>
<td class="Toprule" align="center">0.2</td>
<td class="Toprule" align="center">0.0</td>
</tr>
<tr>
<td class="Toprule" colspan="5">Gastrointestinal Symptoms:</td>
</tr>
<tr>
<td>Diarrhea</td>
<td align="center">5.6</td>
<td align="center">2.9</td>
<td align="center">0.6</td>
<td align="center">0.0</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td align="center">4.3</td>
<td align="center">2.9</td>
<td align="center">0.4</td>
<td align="center">0.0</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td align="center">2.4</td>
<td align="center">1.5</td>
<td align="center">0.4</td>
<td align="center">0.0</td>
</tr>
<tr>
<td>Nausea</td>
<td align="center">2.6</td>
<td align="center">2.9</td>
<td align="center">0.2</td>
<td align="center">0.0</td>
</tr>
<tr>
<td>Flatulence</td>
<td align="center">2.2</td>
<td align="center">2.2</td>
<td align="center">0.0</td>
<td align="center">0.0</td>
</tr>
<tr>
<td class="Toprule" colspan="5">Dermatological Symptoms:</td>
</tr>
<tr>
<td>Rash</td>
<td align="center">5.6</td>
<td align="center">2.2</td>
<td align="center">0.9</td>
<td align="center">0.7</td>
</tr>
<tr>
<td>Pruritus</td>
<td align="center">2.8</td>
<td align="center">1.5</td>
<td align="center">0.2</td>
<td align="center">0.0</td>
</tr>
<tr>
<td>Urticaria</td>
<td align="center">1.1</td>
<td align="center">0.0</td>
<td align="center">0.0</td>
<td align="center">0.0</td>
</tr>
<tr>
<td class="Toprule">Liver Enzyme Abnormalities<a class="Sup" href=
"#footnote-1" name="footnote-reference-1" id=
"footnote-reference-1">*</a></td>
<td class="Toprule" align="center">3.3</td>
<td class="Toprule" align="center">1.4</td>
<td class="Toprule" align="center">0.2</td>
<td class="Toprule" align="center">0.0</td>
</tr>
<tr>
<td class="Toprule">Taste Disturbance</td>
<td class="Toprule" align="center">2.8</td>
<td class="Toprule" align="center">0.7</td>
<td class="Toprule" align="center">0.2</td>
<td class="Toprule" align="center">0.0</td>
</tr>
<tr class="Last">
<td class="Toprule">Visual Disturbance</td>
<td class="Toprule" align="center">1.1</td>
<td class="Toprule" align="center">1.5</td>
<td class="Toprule" align="center">0.9</td>
<td class="Toprule" align="center">0.0</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s6p2" id=
"s6p2"></a> <a name="section-6.2" id="section-6.2"></a>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse events have been identified
during postapproval use of Lamisil Tablets. Because these events
are reported voluntarily from a population of uncertain size, it is
not always possible to reliably estimate their frequency or
establish a causal relationship to drug exposure.</p>
<p><span class="Italics">Blood and lymphatic system
disorders:</span> Pancytopenia, agranulocytosis, severe
neutropenia, thrombocytopenia, anemia [see <span class=
"Italics">Warnings and Precautions (5.5)</span>]</p>
<p><span class="Italics">Immune system disorders:</span> Serious
hypersensitivity reactions e.g., angioedema and allergic reactions
(including anaphylaxis), precipitation and exacerbation of
cutaneous and systemic lupus erythematosus [see <span class=
"Italics">Warnings and Precautions (5.7)</span>], serum
sickness-like reaction</p>
<p><span class="Italics">Psychiatric disorders:</span> Anxiety and
depressive symptoms independent of taste disturbance have been
reported with use of Lamisil Tablets. In some cases, depressive
symptoms have been reported to subside with discontinuance of
therapy and to recur with reinstitution of therapy [see
<span class="Italics">Warnings and Precautions (5.4)</span>].</p>
<p><span class="Italics">Nervous system disorders:</span> Cases of
taste disturbance, including taste loss, have been reported with
the use of Lamisil Tablets. It can be severe enough to result in
decreased food intake, weight loss, anxiety, and depressive
symptoms. Cases of smell disturbance, including smell loss, have
been reported with the use of Lamisil Tablets [see <span class=
"Italics">Warnings and Precautions (5.2, 5.3)</span>]. Cases of
paresthesia and hypoesthesia have been reported with the use of
Lamisil Tablets.</p>
<p><span class="Italics">Eye disorders:</span> Visual field
defects, reduced visual acuity</p>
<p><span class="Italics">Ear and labyrinth disorders:</span>
Hearing impairment, vertigo, tinnitus</p>
<p><span class="Italics">Vascular disorders:</span> Vasculitis</p>
<p><span class="Italics">Gastrointestinal disorders:</span>
Pancreatitis, vomiting</p>
<p><span class="Italics">Hepatobiliary disorders:</span> Cases of
liver failure some leading to liver transplant or death [see
<span class="Italics">Warnings and Precautions (5.1)</span>],
idiosyncratic and symptomatic hepatic injury. Cases of hepatitis,
cholestasis, and increased hepatic enzymes [see <span class=
"Italics">Warnings and Precautions (5.1)</span>] have been seen
with the use of Lamisil Tablets.</p>
<p><span class="Italics">Skin and subcutaneous tissue
disorders:</span> Serious skin reactions [e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis, erythema multiforme,
exfoliative dermatitis, bullous dermatitis, and drug reaction with
eosinophilia and systemic symptoms (DRESS) syndrome] [see
<span class="Italics">Warnings and Precautions (5.6)</span>], acute
generalized exanthematous pustulosis, psoriasiform eruptions or
exacerbation of psoriasis, photosensitivity reactions, hair
loss</p>
<p><span class="Italics">Musculoskeletal and connective tissue
disorders:</span> Rhabdomyolysis, arthralgia, myalgia</p>
<p><span class="Italics">General disorders and administration site
conditions:</span> Malaise, fatigue, influenza-like illness,
pyrexia</p>
<p><span class="Italics">Investigations:</span> Altered prothrombin
time (prolongation and reduction) in patients concomitantly treated
with warfarin and increased blood creatine phosphokinase have been
reported</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">7 DRUG INTERACTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34073-7"><a name="s7" id="s7"></a> <a name="section-7" id=
"section-7"></a>
<div class="Section" data-sectioncode="42229-5"><a name="s7p1" id=
"s7p1"></a> <a name="section-7.1" id="section-7.1"></a>
<h2>7.1 Drug-Drug Interactions</h2>
<p class="First"><span class="Italics">In vivo</span> studies have
shown that terbinafine is an inhibitor of the CYP450 2D6 isozyme.
Drugs predominantly metabolized by the CYP450 2D6 isozyme include
the following drug classes: tricyclic antidepressants, selective
serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class
1C (e.g., flecainide and propafenone) and monoamine oxidase
inhibitors Type B. Coadministration of Lamisil Tablets should be
done with careful monitoring and may require a reduction in dose of
the 2D6-metabolized drug. In a study to assess the effects of
terbinafine on desipramine in healthy volunteers characterized as
normal metabolizers, the administration of terbinafine resulted in
a 2-fold increase in C<span class="Sub">max</span> and a 5-fold
increase in area under the curve (AUC). In this study, these
effects were shown to persist at the last observation at 4 weeks
after discontinuation of Lamisil Tablets. In studies in healthy
subjects characterized as extensive metabolizers of
dextromethorphan (antitussive drug and CYP2D6 probe substrate),
terbinafine increases the dextromethorphan/dextrorphan metabolite
ratio in urine by 16- to 97-fold on average. Thus, terbinafine may
convert extensive CYP2D6 metabolizers to poor metabolizer
status.</p>
<p><span class="Italics">In vitro</span> studies with human liver
microsomes showed that terbinafine does not inhibit the metabolism
of tolbutamide, ethinylestradiol, ethoxycoumarin, cyclosporine,
cisapride and fluvastatin. <span class="Italics">In</span>
<span class="Italics">vivo</span> drug-drug interaction studies
conducted in healthy volunteer subjects showed that terbinafine
does not affect the clearance of antipyrine or digoxin. Terbinafine
decreases the clearance of caffeine by 19%. Terbinafine increases
the clearance of cyclosporine by 15%.</p>
<p>The influence of terbinafine on the pharmacokinetics of
fluconazole, cotrimoxazole (trimethoprim and sulfamethoxazole),
zidovudine or theophylline was not considered to be clinically
significant.</p>
<p>Coadministration of a single dose of fluconazole (100 mg) with a
single dose of terbinafine resulted in a 52% and 69% increase in
terbinafine C<span class="Sub">max</span> and AUC, respectively.
Fluconazole is an inhibitor of CYP2C9 and CYP3A enzymes. Based on
this finding, it is likely that other inhibitors of both CYP2C9 and
CYP3A4 (e.g., ketoconazole, amiodarone) may also lead to a
substantial increase in the systemic exposure (C<span class=
"Sub">max</span> and AUC) of terbinafine when concomitantly
administered.</p>
<p>There have been spontaneous reports of increase or decrease in
prothrombin times in patients concomitantly taking oral terbinafine
and warfarin, however, a causal relationship between Lamisil
Tablets and these changes has not been established.</p>
<p>Terbinafine clearance is increased 100% by rifampin, a CYP450
enzyme inducer, and decreased 33% by cimetidine, a CYP450 enzyme
inhibitor. Terbinafine clearance is unaffected by cyclosporine.
There is no information available from adequate drug-drug
interaction studies with the following classes of drugs: oral
contraceptives, hormone replacement therapies, hypoglycemics,
phenytoins, thiazide diuretics, and calcium channel blockers.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-7.2" id="section-7.2"></a>
<h2>7.2 Food Interactions</h2>
<p class="First">An evaluation of the effect of food on Lamisil
Tablets was conducted. An increase of less than 20% of the AUC of
terbinafine was observed when Lamisil Tablets were administered
with food. Lamisil Tablets can be taken with or without food.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">8 USE IN SPECIFIC POPULATIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"43684-0"><a name="section-8" id="section-8"></a>
<div class="Section" data-sectioncode="42228-7"><a name=
"section-8.1" id="section-8.1"></a>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category B</p>
<p>There are no adequate and well-controlled studies in pregnant
women. Because animal reproduction studies are not always
predictive of human response, and because treatment of
onychomycosis can be postponed until after pregnancy is completed,
it is recommended that Lamisil Tablets not be initiated during
pregnancy.</p>
<p>Oral reproduction studies have been performed in rabbits and
rats at doses up to 300 mg/kg/day [12x to 23x the maximum
recommended human dose (MRHD), in rabbits and rats, respectively,
based on body surface area (BSA) comparisons] and have revealed no
evidence of impaired fertility or harm to the fetus due to
terbinafine.</p>
</div>
<div class="Section" data-sectioncode="34080-2"><a name=
"section-8.2" id="section-8.2"></a>
<h2>8.3 Nursing Mothers</h2>
<p class="First">After oral administration, terbinafine is present
in breast milk of nursing mothers. The ratio of terbinafine in milk
to plasma is 7:1. Treatment with Lamisil Tablets is not recommended
in women who are nursing.</p>
</div>
<div class="Section" data-sectioncode="34081-0"><a name=
"section-8.3" id="section-8.3"></a>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and efficacy of Lamisil Tablets have
not been established in pediatric patients with onychomycosis.</p>
</div>
<div class="Section" data-sectioncode="34082-8"><a name=
"section-8.4" id="section-8.4"></a>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of Lamisil Tablets did not
include sufficient numbers of subjects aged 65 years and over to
determine whether they respond differently from younger subjects.
Other reported clinical experience has not identified differences
in responses between the elderly and younger patients. In general,
dose selection for an elderly patient should be cautious, usually
starting at the low end of the dosing range, reflecting the greater
frequency of decreased hepatic, renal, or cardiac function, and of
concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-8.5" id="section-8.5"></a>
<h2>8.6 Renal Impairment</h2>
<p class="First">In patients with renal impairment (creatinine
clearance less than or equal to 50 mL/min) the use of Lamisil
Tablets has not been adequately studied.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">10 OVERDOSAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34088-5"><a name="section-9" id="section-9"></a>
<p class="First">Clinical experience regarding overdose with oral
terbinafine is limited. Doses up to 5 grams (20 times the
therapeutic daily dose) have been taken without inducing serious
adverse reactions. The symptoms of overdose included nausea,
vomiting, abdominal pain, dizziness, rash, frequent urination, and
headache.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">11 DESCRIPTION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34089-3"><a name="section-10" id="section-10"></a>
<p class="First">Lamisil Tablets contain the synthetic allylamine
antifungal compound terbinafine hydrochloride.</p>
<p>Chemically, terbinafine hydrochloride is (E)-<span class=
"Italics">N</span>-(6,6-dimethyl-2-hepten-4-ynyl)-<span class=
"Italics">N</span>-methyl-1-naphthalenemethanamine hydrochloride.
The empirical formula C<span class="Sub">21</span>H<span class=
"Sub">26</span>CIN with a molecular weight of 327.90, and the
following structural formula:</p>
<p><img src=
"image.cfm?setid=7c6c1494-fb92-4442-bcff-764b77397495&amp;name=lamisil-tablets-01.jpg"
alt="terbinafine hydrochloride structural formula "></p>
<p>Terbinafine hydrochloride is a white to off-white fine
crystalline powder. It is freely soluble in methanol and methylene
chloride, soluble in ethanol, and slightly soluble in water.</p>
<p><span class="Bold Italics">Each tablet contains:</span></p>
<p><span class="Italics">Active Ingredients:</span> terbinafine
hydrochloride (equivalent to 250 mg base)</p>
<p><span class="Italics">Inactive Ingredients:</span> colloidal
silicon dioxide NF, hydroxypropyl methylcellulose USP, magnesium
stearate NF, microcrystalline cellulose NF, and sodium starch
glycolate NF.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">12 CLINICAL PHARMACOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"34090-1"><a name="section-11" id="section-11"></a>
<div class="Section" data-sectioncode="43679-0"><a name=
"section-11.1" id="section-11.1"></a>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Terbinafine is an allylamine antifungal [see
<span class="Italics">Clinical Pharmacology (12.4)</span>].</p>
</div>
<div class="Section" data-sectioncode="43681-6"><a name=
"section-11.2" id="section-11.2"></a>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The pharmacodynamics of Lamisil Tablets is
unknown.</p>
</div>
<div class="Section" data-sectioncode="43682-4"><a name=
"section-11.3" id="section-11.3"></a>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Following oral administration, terbinafine is well
absorbed (&gt;70%) and the bioavailability of Lamisil Tablets as a
result of first-pass metabolism is approximately 40%. Peak plasma
concentrations of 1 µg/mL appear within 2 hours after a single 250
mg dose; the AUC is approximately 4.56 µg<span class=
"Sup">.</span>h/mL. An increase in the AUC of terbinafine of less
than 20% is observed when Lamisil Tablets are administered with
food.</p>
<p>In plasma, terbinafine is &gt;99% bound to plasma proteins and
there are no specific binding sites. At steady-state, in comparison
to a single dose, the peak concentration of terbinafine is 25%
higher and plasma AUC increases by a factor of 2.5; the increase in
plasma AUC is consistent with an effective half-life of ~36 hours.
Terbinafine is distributed to the sebum and skin. A terminal
half-life of 200-400 hours may represent the slow elimination of
terbinafine from tissues such as skin and adipose. Prior to
excretion, terbinafine is extensively metabolized by at least 7 CYP
isoenzymes with major contributions from CYP2C9, CYP1A2, CYP3A4,
CYP2C8, and CYP2C19. No metabolites have been identified that have
antifungal activity similar to terbinafine. Approximately 70% of
the administered dose is eliminated in the urine.</p>
<p>In patients with renal impairment (creatinine clearance
<span class="Underline">&lt;</span>50 mL/min) or hepatic cirrhosis,
the clearance of terbinafine is decreased by approximately 50%
compared to normal volunteers. No effect of gender on the blood
levels of terbinafine was detected in clinical trials. No
clinically relevant age-dependent changes in steady-state plasma
concentrations of terbinafine have been reported.</p>
</div>
<div class="Section" data-sectioncode="49489-8"><a name=
"section-11.4" id="section-11.4"></a>
<h2>12.4 Microbiology</h2>
<p class="First">Terbinafine, an allylamine antifungal, inhibits
biosynthesis of ergosterol, an essential component of fungal cell
membrane, via inhibition of squalene epoxidase enzyme. This results
in fungal cell death primarily due to the increased membrane
permeability mediated by the accumulation of high concentrations of
squalene but not due to ergosterol deficiency. Depending on the
concentration of the drug and the fungal species test <span class=
"Italics">in vitro</span>, terbinafine hydrochloride may be
fungicidal. However, the clinical significance of <span class=
"Italics">in vitro</span> data is unknown.</p>
<p>Terbinafine has been shown to be active against most strains of
the following microorganisms both in vitro and in clinical
infections:</p>
<p><span class="Italics">Trichophyton</span> <span class=
"Italics">mentagrophytes</span></p>
<p><span class="Italics">Trichophyton</span> <span class=
"Italics">rubrum</span></p>
<p>The following <span class="Italics">in vitro</span> data are
available, but their clinical significance is unknown. <span class=
"Italics">In vitro</span>, terbinafine exhibits satisfactory MIC’s
against most strains of the following microorganisms; however, the
safety and efficacy of terbinafine in treating clinical infections
due to these microorganisms have not been established in adequate
and well-controlled clinical trials:</p>
<p><span class="Italics">Candida</span> <span class=
"Italics">albicans</span></p>
<p><span class="Italics">Epidermophyton</span> <span class=
"Italics">floccosum</span></p>
<p><span class="Italics">Scopulariopsis</span> <span class=
"Italics">brevicaulis</span></p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">13 NONCLINICAL TOXICOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"43680-8"><a name="section-12" id="section-12"></a>
<div class="Section" data-sectioncode="34083-6"><a name=
"section-12.1" id="section-12.1"></a>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a 28-month oral carcinogenicity study in rats,
an increase in the incidence of liver tumors was observed in males
at the highest dose tested, 69 mg/kg/day (2x the MRHD based on AUC
comparisons of the parent terbinafine); however, even though
dose-limiting toxicity was not achieved at the highest tested dose,
higher doses were not tested.</p>
<p>The results of a variety of <span class="Italics">in
vitro</span> (mutations in <span class="Italics">E. coli</span> and
<span class="Italics">S.</span> <span class=
"Italics">typhimurium</span>, DNA repair in rat hepatocytes,
mutagenicity in Chinese hamster fibroblasts, chromosome aberration,
and sister chromatid exchanges in Chinese hamster lung cells), and
<span class="Italics">in vivo</span> (chromosome aberration in
Chinese hamsters, micronucleus test in mice) genotoxicity tests
gave no evidence of a mutagenic or clastogenic potential.</p>
<p>Oral reproduction studies in rats at doses up to 300 mg/kg/day
(approximately 12x the MRHD based on BSA comparisons) did not
reveal any specific effects on fertility or other reproductive
parameters. Intravaginal application of terbinafine hydrochloride
at 150 mg/day in pregnant rabbits did not increase the incidence of
abortions or premature deliveries nor affect fetal parameters.</p>
</div>
<div class="Section" data-sectioncode="34091-9"><a name=
"section-12.2" id="section-12.2"></a>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">A wide range of <span class="Italics">in
vivo</span> studies in mice, rats, dogs, and monkeys, and
<span class="Italics">in vitro</span> studies using rat, monkey,
and human hepatocytes suggest that peroxisome proliferation in the
liver is a rat-specific finding. However, other effects, including
increased liver weights and APTT, occurred in dogs and monkeys at
doses giving Css trough levels of the parent terbinafine 2-3x those
seen in humans at the MRHD. Higher doses were not tested.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">14 CLINICAL STUDIES</a>
<div class="Section toggle-content closed" data-sectioncode=
"34092-7"><a name="section-13" id="section-13"></a>
<p class="First">The efficacy of Lamisil Tablets in the treatment
of onychomycosis is illustrated by the response of subjects with
toenail and/or fingernail infections who participated in 3
US/Canadian placebo-controlled clinical trials.</p>
<p>Results of the first toenail trial, as assessed at week 48 (12
weeks of treatment with 36 weeks follow-up after completion of
therapy), demonstrated mycological cure, defined as simultaneous
occurrence of negative KOH plus negative culture, in 70% of
subjects. Fifty-nine percent (59%) of subjects experienced
effective treatment (mycological cure plus 0% nail involvement or
&gt;5mm of new unaffected nail growth); 38% of subjects
demonstrated mycological cure plus clinical cure (0% nail
involvement).</p>
<p>In a second toenail trial of dermatophytic onychomycosis, in
which nondermatophytes were also cultured, similar efficacy against
the dermatophytes was demonstrated. The pathogenic role of the
nondermatophytes cultured in the presence of dermatophytic
onychomycosis has not been established. The clinical significance
of this association is unknown.</p>
<p>Results of the fingernail trial, as assessed at week 24 (6 weeks
of treatment with 18 weeks follow-up after completion of therapy),
demonstrated mycological cure in 79% of subjects, effective
treatment in 75% of the subjects, and mycological cure plus
clinical cure in 59% of the subjects.</p>
<p>The mean time to overall success was approximately 10 months for
the first toenail trial and 4 months for the fingernail trial. In
the first toenail trial, for subjects evaluated at least 6 months
after achieving clinical cure and at least 1 year after completing
therapy with Lamisil Tablets, the clinical relapse rate was
approximately 15%.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">16 HOW SUPPLIED/STORAGE AND HANDLING</a>
<div class="Section toggle-content closed" data-sectioncode=
"34069-5"><a name="section-14" id="section-14"></a>
<p class="First">Lamisil Tablets are supplied as white to
yellow-tinged white circular, bi-convex, beveled tablets containing
250 mg of terbinafine imprinted with “LAMISIL” in circular form on
one side and code “250” on the other.</p>
<p>Bottles of 100 tablets NDC 0078-0179-05</p>
<p>Bottles of 30 tablets NDC 0078-0179-15</p>
<p>Store Lamisil Tablets below 25°C (77°F); in a tight container.
Protect from light.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">17 PATIENT COUNSELING INFORMATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34076-0"><a name="section-15" id="section-15"></a>
<p class="First">See FDA-Approved Patient Labeling (Patient
Information)</p>
<p>Patients taking Lamisil Tablets should receive the following
information and instructions:</p>
<ul>
<li>Advise patients to immediately report to their physician or get
emergency help if they experience any of the following symptoms:
hives, mouth sores, blistering and peeling of skin, swelling of
face, lips, tongue, or throat, difficulty swallowing or breathing.
Lamisil Tablets treatment should be discontinued.</li>
<li>Advise patients to immediately report to their physician any
symptoms of persistent nausea, anorexia, fatigue, vomiting, right
upper abdominal pain, jaundice, dark urine, or pale stools. Lamisil
Tablets treatment should be discontinued.</li>
<li>Advise patients to report to their physician any signs of taste
disturbance, smell disturbance and/or depressive symptoms, fever,
skin eruption, lymph node enlargement, erythema, scaling, loss of
pigment, and unusual photosensitivity that can result in a rash.
Lamisil Tablets treatment should be discontinued.</li>
<li>Advise patients to minimize exposure to natural and artificial
sunlight (tanning beds or UVA/B treatment) while using Lamisil
Tablets.</li>
<li>Advise patients that if they forget to take Lamisil Tablets, to
take their tablets as soon as they remember, unless it is less than
4 hours before the next dose is due. Advise patients to call their
physician if they take too many Lamisil Tablets.</li>
</ul>
<p>T2015-13<br>
February 2015</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PATIENT PACKAGE INSERT</a>
<div class="Section toggle-content closed" data-sectioncode=
"42230-3"><a name="section-16" id="section-16"></a>
<p class="First"><span class="Bold">Patient Information</span></p>
<p>Lamisil (Lam-i-sil)</p>
<p>(terbinafine hydrochloride)</p>
<p>Tablets</p>
<p><span class="Bold">What are Lamisil Tablets?</span></p>
<p>Lamisil Tablets is a prescription antifungal medicine used to
treat fungal infections of the fingernails and toenails
(onychomycosis).</p>
<p>Your doctor should do tests to check you for fungal infection of
your nails before you start Lamisil Tablets.</p>
<p>It is not known if Lamisil Tablets are safe and effective in
children for the treatment of onychomycosis.</p>
<p><span class="Bold">Who should not take Lamisil
Tablets?</span></p>
<p>Do not take Lamisil Tablets if you are allergic to terbinafine
hydrochloride when taken by mouth.</p>
<p><span class="Bold">What should I tell my doctor before taking
Lamisil Tablets?</span></p>
<p><span class="Bold">Before you take Lamisil Tablets, tell your
doctor if you:</span></p>
<ul>
<li>have or had liver problems</li>
<li>have a weakened immune system (immunocompromised)</li>
<li>have lupus (an autoimmune disease)</li>
<li>have any other medical conditions</li>
<li>are pregnant or plan to become pregnant. It is not known if
Lamisil Tablets will harm your unborn baby. You should not start
taking Lamisil Tablets during pregnancy without talking with your
doctor.</li>
<li>are breastfeeding or plan to breastfeed. Lamisil can pass into
your breast milk and may harm your baby. Talk to your doctor about
the best way to feed your baby if you take Lamisil Tablets.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you
take,</span> including prescription and over-the-counter medicines,
vitamins, and herbal supplements.</p>
<p>Lamisil Tablets may affect the way other medicines work and
other medicines may affect how Lamisil Tablets work. Especially
tell your doctor if you take:</p>
<ul>
<li>a medicine for depression</li>
<li>a medicine for high blood pressure</li>
<li>a medicine for heart problems</li>
<li>desipramine (Norpramin)</li>
<li>caffeine</li>
<li>cyclosporine (Gengraf, Neoral, Sandimmune)</li>
<li>fluconazole (Diflucan)</li>
<li>rifampin (Rifater, Rifamate, Rimactane, Rifadine)</li>
<li>cimetidine (Tagamet)</li>
</ul>
<p>If you are not sure if your medicine is one listed above, ask
your doctor or pharmacist.</p>
<p>Know the medicines you take. Keep a list of them to show your
doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take Lamisil Tablets?</span></p>
<ul>
<li>Take Lamisil Tablets exactly as your doctor tells you to take
it.</li>
<li>Lamisil comes as a tablet that you take by mouth.</li>
<li><span class="Bold">Lamisil Tablets are usually taken:</span>
<ul>
<li><span class="Bold">1 time each day for 6 weeks to treat fungal
infections of your fingernail, or</span></li>
<li><span class="Bold">1 time each day for 12 weeks to treat fungal
infections of your toenail</span></li>
</ul>
</li>
<li>Lamisil Tablets can be taken with or without food.</li>
<li>If you miss a dose of Lamisil Tablets, take it as soon as you
remember. If it is less than 4 hours before your next dose, skip
the missed dose. Just take the next dose at your regular time.</li>
</ul>
<p>If you take too many Lamisil Tablets call your doctor. You may
have the following symptoms:</p>
<ul>
<li>nausea</li>
<li>vomiting</li>
<li>stomach (abdomen) pain</li>
<li>dizziness</li>
<li>rash</li>
<li>frequent urination</li>
<li>headache</li>
</ul>
<p><span class="Bold">What should I avoid while taking Lamisil
Tablets?</span></p>
<ul>
<li>Avoid sunlight. Lamisil Tablets can make your skin sensitive to
the sun and the light from sunlamps and tanning beds. You can get a
severe sunburn. Use sunscreen and wear a hat and clothes that cover
your skin if you have to be in sunlight. Talk to your doctor if you
get sunburn.</li>
</ul>
<p><span class="Bold">What are the possible side effects of Lamisil
Tablets?</span></p>
<p><span class="Bold">Lamisil Tablets may cause serious side
effects, including:</span></p>
<ul>
<li><span class="Bold">liver problems that can lead to the need for
liver transplant, or death.</span> Tell your doctor right away if
you get any of these symptoms of a liver problem:
<ul>
<li>nausea</li>
<li>upper right stomach-area (abdomen) pain</li>
<li>poor appetite</li>
<li>yellowing of your skin or eyes (jaundice)</li>
<li>tiredness</li>
<li>dark (tea-colored) urine</li>
<li>vomiting</li>
<li>pale or light colored stools</li>
</ul>
</li>
</ul>
<p>Your doctor should do a blood test to check you for liver
problems before you take Lamisil Tablets.</p>
<ul>
<li><span class="Bold">change in taste or loss of taste</span> may
happen with Lamisil Tablets and can be severe. This may improve
within several weeks after you stop taking Lamisil Tablets, but may
last for a long time or may become permanent. Tell your doctor if
you have:
<ul>
<li>change in taste or loss of taste</li>
<li>poor appetite</li>
<li>unwanted weight loss</li>
<li>anxiousness</li>
<li>change in mood or depressive symptoms</li>
</ul>
</li>
<li><span class="Bold">change in smell or loss of smell</span> may
happen with Lamisil Tablets. This may improve after you stop taking
Lamisil Tablets, but may last for a long time or may become
permanent.</li>
<li><span class="Bold">depressive symptoms. Tell your doctor right
away if you have any of these signs or symptoms:</span>
<ul>
<li>feel sad or worthless</li>
<li>change in sleep pattern</li>
<li>loss of energy or interest in daily activities</li>
<li>restlessness</li>
<li>mood changes</li>
</ul>
</li>
<li><span class="Bold">low white blood cell count.</span> People
taking Lamisil Tablets may have a decrease in white blood cells,
especially neutrophils. You may have a higher risk of getting an
infection when your white blood cell count is low.</li>
<li><span class="Bold">serious skin or allergic reactions.</span>
Tell your doctor right away or get emergency help if you get any of
these symptoms:
<ul>
<li>skin rash, hives, sores in your mouth, or your skin blisters
and peels</li>
<li>swelling of your face, eyes, lips, tongue or throat, trouble
swallowing or breathing</li>
<li>drug reaction with eosinophilia and systemic symptoms (DRESS)
syndrome – skin rash, fever, swollen lymph glands, involvement of
internal organs</li>
</ul>
</li>
<li><span class="Bold">new or worsening lupus (an autoimmune
disease).</span> Stop taking Lamisil Tablets and tell your doctor
if you get any of the following:
<ul>
<li>progressive skin rash that is scaly, red, shows scarring, or
loss of pigment</li>
<li>unusual sensitivity to the sun that can lead to a rash</li>
</ul>
</li>
</ul>
<p>The most common side effects of Lamisil Tablets include:</p>
<ul>
<li>headache</li>
<li>diarrhea</li>
<li>rash</li>
<li>upset stomach</li>
<li>abnormal liver function tests</li>
<li>itching</li>
<li>change in taste</li>
<li>nausea</li>
<li>stomach-area (abdomen) pain</li>
<li>gas</li>
</ul>
<p>Tell your doctor if you have any side effect that bothers you or
that does not go away.</p>
<p>These are not all of the possible side effects of Lamisil
Tablets. For information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may
report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store Lamisil
Tablets?</span></p>
<ul>
<li>Store Lamisil Tablets below 77°F (25°C)</li>
<li>Keep Lamisil Tablets in a tightly closed container and keep out
of the light.</li>
</ul>
<p><span class="Bold">Keep Lamisil Tablets and all medicines out of
the reach of children.</span></p>
<p><span class="Bold">General information about the safe and
effective use of Lamisil Tablets.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those
listed in Patient Information. Do not use Lamisil Tablets for a
condition for which it was not prescribed. Do not give Lamisil
Tablets to other people, even if they have the same symptoms that
you have. It may harm them.</p>
<p>You can ask your pharmacist or doctor for information about
Lamisil Tablets that is written for health professionals.</p>
<p><span class="Bold">What are the ingredients in Lamisil
Tablets?</span></p>
<p>Active ingredient: terbinafine hydrochloride</p>
<p>Inactive ingredients: colloidal silicon dioxide, hydroxypropyl
methylcellulose, magnesium stearate, microcrystalline cellulose,
sodium starch glycolate</p>
<p>This Patient Information has been approved by the U.S. Food and
Drug Administration.</p>
<p>Distributed by:<br>
Novartis Pharmaceuticals Corporation<br>
East Hanover, New Jersey 07936</p>
<p>© Novartis</p>
<p>T2015-14<br>
February 2015</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="section-17" id="section-17"></a>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY
PANEL</span></p>
<p><span class="Bold">Package Label – 250 mg Tablets</span></p>
<p>Rx Only NDC 0078-0179-15</p>
<p>LAMISIL® (terbinafine hydrochloride)</p>
<p>30 Tablets</p>
<p>250 mg</p>
<p>Tablets equivalent to 250 mg base</p>
<p><img src=
"image.cfm?setid=7c6c1494-fb92-4442-bcff-764b77397495&amp;name=lamisil-tablets-02.jpg"
alt=
"PRINCIPAL DISPLAY PANEL – PACKAGE LABEL – 30 TABLETS - 250 MG."></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">INGREDIENTS AND APPEARANCE</a>
<div class="DataElementsTables toggle-content">
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>LAMISIL</strong><br>
<span class="contentTableReg">terbinafine hydrochloride
tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0078-0179</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TERBINAFINE HYDROCHLORIDE</strong>
(UNII: 012C11ZU6G) (TERBINAFINE - UNII:G7RIW8S0XP)</td>
<td class="formItem">TERBINAFINE</td>
<td class="formItem">250 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong> (UNII:
ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong> (UNII:
3NXW29V3WO)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A
POTATO</strong> (UNII: 5856J3G2A2)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (whitish to yellow-tinged white)</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (circular)</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LAMISIL;250</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0078-0179-05</td>
<td class="formItem">100 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:0078-0179-15</td>
<td class="formItem">30 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020539</td>
<td class="formItem">05/10/1996</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Labeler -</span> Novartis Pharmaceuticals
Corporation (002147023)</td>
</tr>
</tbody>
</table>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
</ul>
<div class="control-nav"><a class="open-all" href="#">View All
Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
</div>
</div>
</article>
<div class="articlefooternav">
<h2>Find additional resources</h2>
<strong>(also available in the <a href="#leftmenu">left
menu</a>)</strong>
<h3>Safety</h3>
<p><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a>, <a href=
"http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety
Recalls</a>, <a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22TERBINAFINE%22+%29"
target="_blank">Presence in Breast Milk</a></p>
<h3>Related Resources</h3>
<p><a href=
"http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=TERBINAFINE"
target="_blank">Medline Plus</a>, <a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=TERBINAFINE"
target="_blank">Clinical Trials</a>, <a href="#pubmed-menu" id=
"pubmed-bottom">PubMed</a>, <a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=APRD00508&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></p>
<h3>More Info on this Drug</h3>
<p><a href="#modal-label-archives" class="modal-open">View Label
Archives</a>, <a href="#modal-rx-norm" class=
"modal-open">RxNorm</a>, <a href="#modal-label-rss" class=
"modal-open">Get Label RSS Feed</a></p>
</div>
</div>
<div class="divider"></div>
</div>
</div>
<!-- Label Archives Modal -->
<div class="mfp-hide modal" id="modal-label-archives">
<div class="modal-wrapper">
<header>
<h2>View Label Archives for this drug</h2>
</header>
<div class="top">
<h3 class="long-title">LAMISIL- terbinafine hydrochloride
tablet<br></h3>
<h4>Number of versions: 12</h4>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th>Published Date <a class="tip" rel="tooltip" href="#" title=
"&lt;b&gt;Published Date&lt;/b&gt; - The date that a drug label is published on DailyMed for public view. This is distinct from &lt;b&gt;Updated Date&lt;/b&gt;*. &lt;br&gt;&lt;br&gt; *&lt;b&gt;Updated Date&lt;/b&gt; (also known as &lt;b&gt;Effective Time&lt;/b&gt;) - The label revision date included in the SPL.">
(What is this?)</a></th>
<th>Version</th>
<th>Files</th>
</tr>
<tr>
<td>Feb 13, 2015</td>
<td>14 (current)</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=165862">download</a></td>
</tr>
<tr>
<td>Nov 4, 2013</td>
<td>13</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=123272">download</a></td>
</tr>
<tr>
<td>Jul 2, 2013</td>
<td>12</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=112177">download</a></td>
</tr>
<tr>
<td>Aug 1, 2012</td>
<td>11</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=84431">download</a></td>
</tr>
<tr>
<td>Nov 18, 2011</td>
<td>10</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=67541">download</a></td>
</tr>
<tr>
<td>Jun 29, 2011</td>
<td>9</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=57782">download</a></td>
</tr>
<tr>
<td>Apr 14, 2011</td>
<td>8</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=52293">download</a></td>
</tr>
<tr>
<td>Feb 17, 2011</td>
<td>7</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=49416">download</a></td>
</tr>
<tr>
<td>Dec 15, 2010</td>
<td>6</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=44245">download</a></td>
</tr>
<tr>
<td>Jul 14, 2009</td>
<td>4</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=11174">download</a></td>
</tr>
<tr>
<td>Aug 15, 2007</td>
<td>2</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=5207">download</a></td>
</tr>
<tr>
<td>Sep 21, 2006</td>
<td>1</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=1744">download</a></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- RxNorm Modal -->
<div class="mfp-hide modal" id="modal-rx-norm">
<div class="modal-wrapper">
<header>
<h2>RxNorm</h2>
</header>
<div class="top">
<h3 class="long-title">LAMISIL- terbinafine hydrochloride
tablet<br></h3>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th></th>
<th>RxCUI</th>
<th>RxNorm NAME</th>
<th>RxTTY</th>
</tr>
<tr class="psn-rxtty">
<td>1</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=105330">105330</a></td>
<td>LamISIL 250 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>2</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=105330">105330</a></td>
<td>terbinafine 250 MG Oral Tablet [Lamisil]</td>
<td>SBD</td>
</tr>
<tr>
<td>3</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=105330">105330</a></td>
<td>Lamisil (as terbinafine hydrochloride) 250 MG Oral Tablet</td>
<td>SY</td>
</tr>
<tr>
<td>4</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=105330">105330</a></td>
<td>Lamisil 250 MG Oral Tablet</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>5</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=313222">313222</a></td>
<td>terbinafine HCl 250 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>6</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=313222">313222</a></td>
<td>terbinafine 250 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr>
<td>7</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=313222">313222</a></td>
<td>terbinafine (as terbinafine hydrochloride) 250 MG Oral
Tablet</td>
<td>SY</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- Label RSS Modal -->
<div class="mfp-hide modal" id="modal-label-rss">
<header>
<h2>Get Label RSS Feed for this Drug</h2>
</header>
<div class="top">
<h3 class="long-title">LAMISIL- terbinafine hydrochloride
tablet<br></h3>
</div>
<div class="modal-content">
<h4>To receive this label RSS feed</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href=
"https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=7c6c1494-fb92-4442-bcff-764b77397495"
target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=7c6c1494-fb92-4442-bcff-764b77397495</a></p>
<h4>To receive all DailyMed Updates for the last seven days</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>
<h4>What will I get with the DailyMed RSS feed?</h4>
<p>DailyMed will deliver notification of updates and additions to
Drug Label information currently shown on this site through its RSS
feed.</p>
<p>DailyMed will deliver this notification to your desktop, Web
browser, or e-mail depending on the RSS Reader you select to use.
To view updated drug label links, paste the RSS feed address (URL)
shown below into a RSS reader, or use a browser which supports RSS
feeds, such as Safari for Mac OS X.</p>
<h4>How to discontinue the RSS feed</h4>
<p>If you no longer wish to have this DailyMed RSS service, simply
delete the copied URL from your RSS Reader.</p>
<a href="/dailymed/rss-updates.cfm" class="rss-icon"></a> <a href=
"/dailymed/rss-updates.cfm">More about getting RSS News &amp;
Updates from DailyMed</a></div>
</div>
<!-- RxImage no more notification modal -->
<div class="mfp-hide modal" id="no-pill-photo-warning-modal">
<div class="modal-content">
<h4>Why is DailyMed no longer displaying pill images on the Search
Results and Drug Info pages?</h4>
<br>
<p>Due to inconsistencies between the drug labels on DailyMed and
the pill images provided by <a href=
"https://rximage.nlm.nih.gov/docs/doku.php?id=rximageapi_support"
target="_blank">RxImage</a>, we no longer display the RxImage pill
images associated with drug labels.</p>
<p>We anticipate reposting the images once we are able identify and
filter out images that do not match the information provided in the
drug labels.</p>
</div>
</div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<div class="mobilenav no-js">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
<footer class="mainFooter">
<div class="container">
<div class="three columns">
<div class="nihnlmlogoprint"><img src=
"/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>
<a href="//www.nlm.nih.gov/" class="logo" title=
"National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png"
width="109" height="37" alt=
"National Library of Medicine | National Institutes of Health"
title=
"National Library of Medicine | National Institutes of Health"></a></div>
<div id="share" class="thirteen columns">
<div class="footer-links">
<ul class="primary">
<li><a href="/dailymed/about-dailymed.cfm" title=
"About DailyMed">About DailyMed</a><span>|</span></li>
<li><a href="/dailymed/contact-us.cfm" title="Contact Us">Contact
Us</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/copyright.html" title="Copyright"
target="_blank" rel="bookmark">Copyright</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/privacy.html" title="Privacy"
target="_blank" rel="bookmark">Privacy</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/accessibility.html" title=
"Web Accessibility" target="_blank" rel="bookmark">Web
Accessibility</a></li>
</ul>
<ul class="secondary">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">National Institutes of Health</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">U.S. National Library of Medicine</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<ul class="secondary mobile">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">NIH</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">NLM</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<div class="social">Share <!-- AddThis Button BEGIN -->
 <noscript>: JavaScript needed for Sharing tools</noscript>
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0ALAMISIL%2D%20Terbinafine%20Hydrochloride%20Tablet%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D7c6c1494%2Dfb92%2D4442%2Dbcff%2D764b77397495%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="width: 16px; height: 16px"><span style=
"left: -9999px; position: absolute;">Bookmark &amp; Share</span>
<img style="width:17px; margin-top: -2px;" src=
"/dailymed/images/addthis-image.jpg" alt=
"Bookmark &amp; Share"></a></div>
<!-- AddThis Button END --></div>
</div>
</div>
</div>
<div class="divider"></div>
</footer>
<div class="divider"></div>
</div>
<div class="to-top"></div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<script type="text/javascript" src=
"//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery == 'undefined')
        {  
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');
        }
</script> <script type="text/javascript">
        var basepath = "/dailymed";
;
        var availableClasses =  new Array();
;
        for(var i = 0; i < availableClasses.length; i++){
                availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();
        }
        var labeltitle = "LAMISIL- terbinafine hydrochloride tablet <br>";
;
        var emailLink = "";
;
        var emailrequest = "0";
;
</script> <script src=
"/dailymed/scripts/javascript-html-attribute-encoding.min.js">
</script> <script src="/dailymed/scripts/spin.min.js">
</script> <script src="/dailymed/scripts/scripts.min.js?v=2">
</script> <script type='text/javascript' src=
"//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery.ui == 'undefined')
        {
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');
            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="/dailymed/css/jquery-ui-1.10.4.custom.min.css">');
        }
        else{
            document.write('<link rel="stylesheet" href="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');
        }
</script> <script type='text/javascript' src=
'/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'>
</script> <script type="text/javascript" src=
"/dailymed/scripts/jquery.placeholder.min.js">
</script> <script src=
"//www.accessdata.fda.gov/spl/stylesheet/spl.js" type=
"text/javascript" charset="utf-8">
/* */
</script> <!-- Magnific Popup core JS file -->
 <script src="/dailymed/scripts/jquery.magnific-popup.min.js">
</script> <script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <script>
 var ignore_onbeforeunload = false;

 $("a").on('click',function(){
    if(ignore_onbeforeunload){
        ignore_onbeforeunload = false;
    }
})

$("a[href^='mailto'], a[href$='zip']").on('click',function(){
    ignore_onbeforeunload = true;
});


$(window).on('beforeunload', function(){
    if (!ignore_onbeforeunload){
        // Only run the loading icon if changing the page takes longer than 200ms
        setTimeout(function(){
            // Fade in the grey screen
            $('body').prepend($('<div class="loading-wrapper" style="width: 100%;height: 100%;background-color: rgba(0, 0, 0, 0.50);position: fixed;top:0;z-index: 100000;"><\/div>').fadeIn('fast'));
            var opts = {
                  lines: 12 // The number of lines to draw
                , length: 14 // The length of each line
                , width: 5 // The line thickness
                , radius: 14 // The radius of the inner circle
                , scale: 1 // Scales overall size of the spinner
                , corners: 1 // Corner roundness (0..1)
                , color: '#fff' 
                , opacity: 0.25 // Opacity of the lines
                , rotate: 0 // The rotation offset
                , direction: 1 // 1: clockwise, -1: counterclockwise
                , speed: 1 // Rounds per second
                , trail: 60 // Afterglow percentage
                , fps: 20 // Frames per second when using setTimeout() as a fallback for CSS
                , zIndex: 2e9 // The z-index (defaults to 2000000000)
                , className: 'spinner' // The CSS class to assign to the spinner
                , top: '50%' // Top position relative to parent
                , left: '50%' // Left position relative to parent
                , shadow: false // Whether to render a shadow
                , hwaccel: false // Whether to use hardware acceleration
                , position: 'absolute' // Element positioning
                }
            var spinner = new Spinner(opts).spin();
            $('.loading-wrapper').append(spinner.el);
        }, 200);
    }

    //ignore_onbeforeunload = false;
});
</script> <!-- START OF SmartSource Data Collector TAG -->
<!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. -->
<!-- Version: 9.4.0 -->
<!-- Tag Builder Version: 3.3  -->
<!-- Created: 1/25/2012 11:57:33 PM -->
<script type="text/javascript" src=
"/dailymed/scripts/webtrends.min.js">
</script> 
<!-- =================================================================================== -->
<!-- Warning: The two script blocks below must remain inline. Moving them to an external -->
<!-- JavaScript include file can cause serious problems with cross-domain tracking.      -->
<!-- =================================================================================== -->
<script type="text/javascript">
//<![CDATA[
var _tag=new WebTrends();
_tag.dcsGetId();
//]]>
</script> <script type="text/javascript">
//<![CDATA[
_tag.dcsCustom=function(){
// Add custom parameters here.
//_tag.DCSext.param_name=param_value;
_tag.DCSext.dcsid=_tag.dcsid
}
_tag.trackAllEvents=true;
_tag.dcsCollect();
//]]>
</script> <noscript>
<div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src=
"//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"></div>
</noscript> <!-- END OF SmartSource Data Collector TAG -->
 <script type="text/javascript">
    setTimeout(function(){var a=document.createElement("script");
    var b=document.getElementsByTagName("script")[0];
    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);
    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);
</script> <script type="text/javascript">
    function getParameterByName(name) {
        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");
        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),
            results = regex.exec(location.search);
        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));
    }
    /* Tracking label type on search pages */
    function CE_READY() {
        if(!getParameterByName('labeltype')){
           CE2.set(1, "No Label Type");
        }
        else{
            var labeltype = getParameterByName('labeltype');
            if(labeltype == 'all'){
                CE2.set(1, "All");
            }
            else if(labeltype == 'human'){
                CE2.set(1, "Human");
            }
            else if(labeltype == 'animal'){
                CE2.set(1, "Animal");
            }
            else{
                CE2.set(1, "Unknown");
            }
        }
    }
</script> <!-- DAP Universal Analytics -->
 <script language="javascript" id="_fed_an_ua_tag" src=
"/dailymed/scripts/Universal-Federated-Analytics-Min.2.01.js?agency=HHS&amp;subagency=NIH&amp;enhlink=true&amp;dclink=true">
</script> <script src="/dailymed/scripts/preview-text.min.js">
</script>
</body>
</html>
